Literature DB >> 8163716

Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations.

M Kraisinger1, G Hochhaus, A Stecenko, E Bowser, L Hendeles.   

Abstract

Improving protein and fat absorption in patients with cystic fibrosis relates to the amount of biologically active enzyme reaching the duodenum. Microencapsulated formulations are more effective than conventional products but differ in content, ability to retard acid inactivation and the pH at which they release enzymes. Contaminants in these products contribute to hyperuricosuria.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8163716     DOI： 10.1002/j.1552-4604.1994.tb03981.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


  16 in total

1.  Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

Authors:  Daniel Gelfond; Changxing Ma; Jack Semler; Drucy Borowitz
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

Review 2.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

3.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

4.  In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.

Authors:  Robert J Kuhn; Sabine Eyting; Friederike Henniges; Andreas Potthoff
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

Review 5.  Colonic strictures in cystic fibrosis.

Authors:  J A Dodge; C Macpherson
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

Review 6.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

7.  Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.

Authors:  Michael W Konstan; Frank J Accurso; Samya Z Nasr; Richard C Ahrens; Gavin R Graff
Journal:  Clin Investig (Lond)       Date:  2013-08-01

8.  Treatment of Gastrointestinal Problems in Cystic Fibrosis.

Authors:  Maria R. Mascarenhas
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10

Review 9.  Cystic fibrosis in adults. From researcher to practitioner.

Authors:  G P Marelich; C E Cross
Journal:  West J Med       Date:  1996-04

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.